Somatic variation and cancer: therapies lost in the mix
- 5 June 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Human Genetics
- Vol. 130 (1), 79-91
- https://doi.org/10.1007/s00439-011-1010-0
Abstract
Cancer arises as a consequence of mutations in genomes of cancer cells, which over time allow them to proliferate and spread to distant sites. Large-scale sequencing of cancer genomes is revealing an increasing number of potential driver mutations that may allow specific targeting of cancer genes, proteins, and pathways. Comprehensive views of cancer genomes are also revealing enormous heterogeneity of mutation profiles, even among tumours derived from the same organs and having similar pathological characteristics. There are now many examples where mutation profiles observed in tumours have been shown to correlate with clinical features of disease, drug response, and patient outcomes. When ignored, molecular heterogeneity can lead to failures in drug development, as drugs that may have efficacy in subgroups of patients with specific molecular phenotypes may show marginal response when tested in large groups of unselected patients. This article explores issues relevant to the clinical translation of sequence-based mutation profiles in the clinical development of targeted therapies and in the future management of cancer patients.Keywords
This publication has 93 references indexed in Scilit:
- Identification of a Novel TP53 Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AMLJAMA, 2011
- ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record TimeCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Using genetics and genomics strategies to personalize therapy for cancer: Focus on melanomaBiochemical Pharmacology, 2010
- International network of cancer genome projectsNature, 2010
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Translating insights from the cancer genome into clinical practiceNature, 2008
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005